Shopping Cart
Remove All
Your shopping cart is currently empty
EDP-305
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T73414 Copy Product Info
Purity: 97.17%
🥰Excellent
EDP-305 is an orally active, potent, and highly selective non-bile acid farnesoid X receptor (FXR) agonist with EC₅₀ values of 34 nM (chimeric FXR) and 8 nM (full-length FXR). By activating FXR, EDP-305 modulates pathways related to bile acid, lipid, and glucose metabolism and inhibits inflammation and fibrosis-related signaling; consequently, it is used in research on liver diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis, and liver fibrosis. EDP-305 reduces levels of liver lipid accumulation, inflammation, and fibrosis markers while improving liver function parameters, and is regarded as a promising FXR-targeted metabolic modulator.
Cas No. 1933507-63-1
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $117 | - | In Stock | |
| 5 mg | $289 | - | In Stock | |
| 10 mg | $496 | - | In Stock | |
| 25 mg | $987 | - | In Stock | |
| 50 mg | $1,590 | - | In Stock | |
| 100 mg | $2,500 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $392 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.17%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | EDP-305 is an orally active, potent, and highly selective non-bile acid farnesoid X receptor (FXR) agonist with EC₅₀ values of 34 nM (chimeric FXR) and 8 nM (full-length FXR). By activating FXR, EDP-305 modulates pathways related to bile acid, lipid, and glucose metabolism and inhibits inflammation and fibrosis-related signaling; consequently, it is used in research on liver diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis, and liver fibrosis. EDP-305 reduces levels of liver lipid accumulation, inflammation, and fibrosis markers while improving liver function parameters, and is regarded as a promising FXR-targeted metabolic modulator. |
| In vitro | EDP-305 (10 μM, 72 h) directly activates FXR in hepatocytes but not in astrocytes [1]. EDP-305 (0–5 μM, 16 h) increases the expression of the FXR target gene SHP and downregulates CYP7A1 expression in HepaRG hepatocytes [2]. |
| In vivo | EDP-305 (0–30 mg/kg, administered orally via gavage once daily for 2 weeks) reduced serum markers of liver injury in BDL rats and alleviated liver fibrosis in a dose-dependent manner [1]. EDP-305 (0–30 mg/kg, administered orally via gavage once daily for 6 weeks) reduced liver fibrosis in CDAHFD mice in a dose-dependent manner [1]. |
| Molecular Weight | 630.92 |
| Formula | C36H58N2O5S |
| Cas No. | 1933507-63-1 |
| Smiles | O[C@H]1[C@@]2([C@@]([C@]3(C)[C@]([C@H]1CC)(C[C@H](O)CC3)[H])(CC[C@@]4(C)[C@]2(CC[C@@]4([C@@H](CCNC(NS(=O)(=O)C5=CC=C(C(C)(C)C)C=C5)=O)C)[H])[H])[H])[H] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (126.8 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: EDP-305 chemical structure | EDP-305 in vivo | EDP-305 in vitro | EDP-305 formula | EDP-305 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.